SUBOXONE® (buprenorphine and naloxone) sublingual film CIII Buprenorphine (opioid partial agonist‐antagonist) Naloxone (opioid antagonist)

First Page		Document Content
Morphinans Drug rehabilitation Ketones Substance dependence Buprenorphine Naloxone Opioid dependence Drug Addiction Treatment Act Methadone Chemistry Organic chemistry Alcohols		SUBOXONE® (buprenorphine and naloxone) sublingual film CIII Buprenorphine (opioid partial agonist‐antagonist) Naloxone (opioid antagonist) Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 3,65 MB Share Document on Facebook

	Microsoft Word - VLD Packet.FINAL DocID: 1rubZ - View Document
	Atlantic Pharmaceuticals Announces Successful Pre-IND Meeting with the FDA on Immediate Release, Abuse-Deterrent Hydrocodone Atlanta, GA., August 13, 2013. Atlantic Pharmaceuticals, Inc., a specialty pharmaceutical compa DocID: 1rtjz - View Document
	TITAN PHARMACEUTICALS CORPORATE PRESENTATION SUNIL BHONSLE JUNE 2016 © 2016 TITAN PHARMACEUTICALS INC. NASDAQ:TTNP DocID: 1rsmr - View Document
	Sunil Bhonsle Mar 2015 Corporate Presentation DocID: 1rrwl - View Document
	Adapt v13_doc revised DocID: 1rrqr - View Document